Legend Biotech Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Legend Biotech Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|
| cash flows provided by/ (used in), operating activities | |||
| income before tax | -59,788 | -146,812 | -62,495 |
| adjustments for: | |||
| finance income | -13,870 | -17,302 | -18,420 |
| finance costs | 5,475 | 5,820 | 5,676 |
| benefit from inventory reserve | 1,757 | ||
| depreciation of property, plant and equipment | 2,796 | 2,726 | 2,675 |
| loss on disposal of property, plant and equipment | 2 | 3 | 82 |
| amortization of intangible assets | 885 | 482 | 499 |
| depreciation of right-of-use assets | 2,041 | 2,143 | 1,997 |
| fair value loss of warrant liability | |||
| fair value gains on financial assets measured at fair value through profit or loss | -449 | ||
| increase in contract liabilities | 11,645 | ||
| decrease in contract liabilities | -23,826 | ||
| foreign currency exchange (gain)/loss | -49,056 | ||
| equity-settled share-based compensation expense | 18,703 | 12,589 | 12,377 |
| deferred government grant | -157 | -144 | -124 |
| decrease in trade receivables | 96,734 | ||
| decrease/(increase) in prepayments, other receivables and other assets | -16,266 | ||
| decrease in other non-current assets | 77 | ||
| increase in collaboration inventories | -4,470 | -2,818 | |
| increase/(decrease) in trade payables | 19,298 | ||
| increase/(decrease) in other payables and accruals | 10,878 | ||
| decrease in other non-current liabilities | -25 | -1,229 | |
| increase in pledged deposits | |||
| cash from operations | 2,384 | -109,950 | -76,719 |
| interest income received | 13,479 | 14,372 | 16,281 |
| income tax paid | 71 | ||
| interest on lease payments | -416 | -375 | -410 |
| net cash provided by/(used in) operating activities | 15,518 | ||
| note | 2,024 | 0 | 0 |
| cash flows (used in)/ provided by investing activities | |||
| purchase of property, plant and equipment | -6,243 | -4,345 | -5,377 |
| purchase of intangible assets | -2,504 | -96 | |
| prepayment to collaborator for collaboration assets | -16,541 | -18,566 | -27,200 |
| purchase of financial assets measured at fair value through profit or loss | -150,308 | ||
| cash receipts of investment income | 663 | 2,408 | 2,365 |
| proceeds from disposal of property, plant and equipment | -2 | ||
| addition in time deposits | -721,990 | -1,914,455 | -2,516,671 |
| decrease in time deposits | 498,273 | 2,159,986 | 2,336,985 |
| net cash provided by/(used in) investing activities | -396,148 | ||
| cash flows from financing activities | |||
| proceeds from exercise of share options | 1,589 | 621 | 2,682 |
| principal portion of lease payments | -758 | 304 | -1,721 |
| net cash provided by/(used in) financing activities | 831 | ||
| net increase in cash and cash equivalents | -379,799 | ||
| effect of foreign exchange rate changes | -343 | -784 | |
| cash and cash equivalents at beginning of year | 1,277,713 | 0 | |
| cash and cash equivalents at end of period | 897,571 | -269,743 | |
| analysis of balances of cash and cash equivalents | |||
| cash and bank balances | 1,156,674 | -91,813 | |
| less: pledged deposits | 359 | -890 | |
| time deposits | 258,744 | 178,820 | |
| cash and cash equivalents as stated in the statement of financial position | 897,571 | -269,743 | |
| cash and cash equivalents as stated in the statement of cash flows | 897,571 | -269,743 | |
| cash flows from operating activities | |||
| benefit from inventory reserve* | |||
| fair value loss/(gain) of warrant liability | |||
| fair value gains on financial assets measured at fair value change through profit or loss | |||
| foreign currency exchange loss/(gain) | |||
| (increase)/decrease in trade receivables | |||
| (increase)/decrease in prepayments, other receivables and other assets | |||
| decrease/(increase) in other non-current assets | |||
| (increase)/decrease in collaboration inventories* | |||
| government grant received | |||
| (decrease)/increase in trade payables | 3,018 | -4,371 | |
| (decrease)/increase in other payables and accruals | -10,025 | -8,521 | |
| increase/(decrease) in other non-current liabilities | |||
| increase/ | |||
| income tax received | |||
| net cash from operating activities | -95,645 | -60,848 | |
| capex | -4,345 | -5,377 | |
| free cash flows | -99,990 | -66,225 | |
| cash flows from investing activities | |||
| cash received from withdrawal of financial assets measured at fair value through profit or loss | |||
| cash received from withdrawal of financial assets measured at amortized cost | |||
| decrease in pledged deposits | |||
| purchase of financial assets measured at amortized cost | |||
| proceeds from issuance of ordinary shares for institutional investors, net of issuance cost | |||
| proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs | 0 | ||
| proceeds from exercise of warrant by warrant holder, net of issuance cost | 0 | 0 | |
| proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor | |||
| net cash from financing activities | 925 | 961 | |
| cash flows used in operating activities | |||
| fair value gain/(loss) of warrant liability | |||
| foreign currency exchange loss | -17,156 | ||
| increase in prepayments, other receivables and other assets | 101 | ||
| cash flows used in investing activities | |||
| decrease/(addition) of pledged short-term deposits | |||
| net cash from investing activities | -209,072 | ||
| proceeds from registered direct offering, net of issuance costs | |||
| proceeds from issuance of ordinary shares for institutional investors, net of issuance costs | 0 | ||
| fair value (gains)/losses on financial assets measured at fair value through profit or loss | |||
| net increase/(decrease) in cash and cash equivalents | |||
| fair value (gain)/ loss of warrant liability | |||
| fair value loss of convertible redeemable preferred shares | |||
| decrease/(increase) in trade receivables | |||
| (increase)/decrease in collaboration inventories | |||
| increase in other payables and accruals | |||
| repayment of cash advances from related parties | |||
| proceeds from convertible redeemable preferred shares | |||
| proceeds from issuance of ordinary shares for initial public offering, net of issuance costs | |||
| proceeds from issuance of ordinary shares relating to private placement by genscript | |||
| payments of expenses for issuance of convertible redeemable preferred shares | |||
| (reversal of)/benefit from the impairment of trade receivables | |||
| increase in other non-current assets | |||
| decrease/(increase) in inventories | |||
| increase/(decrease) in trade and notes payables | |||
| (decrease)/increase in other non-current liabilities | |||
| (decrease)/increase in contract liabilities | |||
| finance income received | |||
| interest on loan from related party | |||
| net cash flow used in operating activities | |||
| cash advances to related parties | |||
| collection of cash advances to related parties | |||
| addition in pledged deposits | |||
| net cash flows used in investing activities | |||
| proceeds from cash advances from related parties | |||
| proceeds from loans from related parties | |||
| repayments of loans from related parties | |||
| net cash flows from financing activities | |||
| reversal of the impairment of trade receivables | |||
| write-down of inventories to net realizable value | |||
| income from disposal of property, plant and equipment | |||
| amortisation of intangible assets | |||
| fair value loss of warrant lability | |||
| fair value gains on financial assets at fair value change through profit or loss | |||
| equity-settled share-based compensation expenses | |||
| (increase)/decrease in inventories | |||
| (decrease)/increase in trade and notes payables | |||
| decrease of pledged short-term deposits | |||
| net cash flows used in operating activities | |||
| proceeds from disposal of items of property, plant and equipment | |||
| purchase of financial assets at fair value through profit or loss | |||
| cash received from withdrawal of financial assets at fair value through profit or loss | |||
| cash receipts from investment income | |||
| purchase of financial investment measured at amortized cost | |||
| addition of time deposits | |||
| proceeds from issuance of ordinary shares relating to private placement for an institutional investor | |||
| payments of expenses for issuance convertible redeemable preferred shares | |||
| proceeds from exercise of share option | |||
| cash and cash equivalents at beginning of period | |||
| less: pledged short-term deposits | |||
| benefit from/ (reversal of) for the impairment of trade receivables | |||
| foreign currency exchange gain | |||
| increase in inventories | |||
| increase in other non-current liabilities | |||
| increase of pledged short-term deposits | |||
| cash (used in) /from operations | |||
| net cash flow (used in)/from operating activities | |||
| net cash flows (used in)/from operating activities | |||
| addition of short-term time deposits | |||
| decrease in short-term deposits | |||
| addition of pledged short-term deposits | |||
| decrease in pledged short-term deposits | |||
| cash and cash equivalents at end of year |
We provide you with 20 years of cash flow statements for Legend Biotech stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Legend Biotech stock. Explore the full financial landscape of Legend Biotech stock with our expertly curated income statements.
The information provided in this report about Legend Biotech stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.